Sandeep R. Ghorpade

Sandeep R. Ghorpade

Auto-generated profile, based on publicly available information

Sandeep R. Ghorpade

Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, 7701, South Africa

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2023 in RSC Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
SSSauvik Samanta
Sauvik Samanta
SKSumit Kumar
Sumit Kumar
EAEswar K. Aratikatla
Eswar K. Aratikatla
SGSandeep R. Ghorpade
Sandeep R. Ghorpade
Vinayak SinghVinayak Singh
Vinayak Singh
Here, we critically review anti-TB compounds of the imidazo[1,2- a ]pyridine class by discussing their development based on the structure–activity relationship, mode-of-action, and various scaffold hopping strategies over the last decade.

2 May 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PGPreshendren Govender
Preshendren Govender
RMRudolf Müller
Rudolf Müller
KSKawaljit Singh
Kawaljit Singh
VRVirsinha Reddy
Virsinha Reddy
CECharles J. Eyermann
Charles J. Eyermann
GBGreg Basarab
Greg Basarab

20 August 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LKLutete Peguy Khonde
Lutete Peguy Khonde
RMRudolf Müller
Rudolf Müller
GBGrant A. Boyle
Grant A. Boyle
VRVirsinha Reddy
Virsinha Reddy
ANAloysius T. Nchinda
Aloysius T. Nchinda
KCKelly Chibale
Kelly Chibale

25 June 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
GDGodwin Akpeko Dziwornu
Godwin Akpeko Dziwornu
DSDonald Seanego
Donald Seanego
SFStephen Fienberg
Stephen Fienberg
MCMonica Clements
Monica Clements
JFJasmin Ferreira
Jasmin Ferreira
KCKelly Chibale
Kelly Chibale
Structure-activity relationship studies of 2,8-disubstituted-1,5-naphthyridines, previously reported as potent inhibitors of Plasmodium falciparum (Pf) phosphatidylinositol-4-kinase β (PI4K), identified 1,5-naphthyridines with basic groups at 8-position, which retained Plasmodium PI4K inhibitory activity but switched primary mode of action to the host hemoglobin degradation pathway through inhibition of hemozoin formation. These compounds showed minimal off-target inhibitory activity against the human phosphoinositide kinases and MINK1 and MAP4K kinases, which were associated with the teratogenicity and testicular toxicity observed in rats for the PfPI4K inhibitor clinical candidate MMV390048. A representative compound from the series retained activity against field isolates and lab-raised drug-resistant strains of Pf. It was efficacious in the humanized NSG mouse malaria infection model at a single oral dose of 32 mg/kg. This compound was nonteratogenic in the zebrafish embryo model of teratogenicity and has a low predicted human dose, indicating that this series has the potential to deliver a preclinical candidate for malaria.

7 December 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
CWColin R. Wilson
Colin R. Wilson
RGRichard K. Gessner
Richard K. Gessner
AMAtica Moosa
Atica Moosa
RSRonnett Seldon
Ronnett Seldon
DWDigby Warner
Digby Warner
KCKelly Chibale
Kelly Chibale
A BioFocus DPI SoftFocus library of ∼35 000 compounds was screened against Mycobacterium tuberculosis (Mtb) in order to identify novel hits with antitubercular activity. The hits were evaluated in biology triage assays to exclude compounds suggested to function via frequently encountered promiscuous mechanisms of action including inhibition of the QcrB subunit of the cytochrome bc1 complex, disruption of cell–wall homeostasis, and DNA damage. Among the hits that passed this screening cascade, a 6-dialkylaminopyrimidine carboxamide series was prioritized for hit to lead optimization. Compounds from this series were active against clinical Mtb strains, while no cross-resistance to conventional antituberculosis drugs was observed. This suggested a novel mechanism of action, which was confirmed by chemoproteomic analysis leading to the identification of BCG_3193 and BCG_3827 as putative targets of the series with unknown function. Initial structure–activity relationship studies have resulted in compounds with moderate to potent antitubercular activity and improved physicochemical properties.

4 January 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
CMCandice Soares de Melo
Candice Soares de Melo
Vinayak SinghVinayak Singh
Vinayak Singh
AMAlissa Myrick
Alissa Myrick
Sandile SimelaneSandile Simelane
Sandile Simelane
DTDale Taylor
Dale Taylor
SGSandeep R. Ghorpade
Sandeep R. Ghorpade
Phenotypic screening of a Medicines for Malaria Venture compound library against Mycobacterium tuberculosis (Mtb) identified a cluster of pan-active 2-pyrazolylpyrimidinones. The biology triage of these actives using various tool strains of Mtb suggested a novel mechanism of action. The compounds were bactericidal against replicating Mtb and retained potency against clinical isolates of Mtb. Although selected MmpL3 mutant strains of Mtb showed resistance to these compounds, there was no shift in the minimum inhibitory concentration (MIC) against a mmpL3 hypomorph, suggesting mutations in MmpL3 as a possible resistance mechanism for the compounds but not necessarily as the target. RNA transcriptional profiling and the checkerboard board 2D-MIC assay in the presence of varying concentrations of ferrous salt indicated perturbation of the Fe-homeostasis by the compounds. Structure–activity relationship studies identified potent compounds with good physicochemical properties and in vitro microsomal metabolic stability with moderate selectivity over cytotoxicity against mammalian cell lines.